AKYNZEO J Code: J8655

Drug & Product Overview

HCPCS Descriptor Netupitant 300 mg and palonosetron 0.5 mg, oral

HCPCS Added Date January 1, 2016

Manufacturer Helsinn Therapeutics US

Route of Administration Oral

Generic Status Single-Source; Branded

Dosage Type Single-Dose

Dosage Form Capsule

About AKYNZEO

Akynzeo is a medication aligned to the HCPCS J Code: J8655 for billing, pricing, and reimbursement purposes in the United States. This Anti-Emetic medication is administered via the oral route and manufactured by Helsinn Therapeutics US.

Manufacturers, reach out to us to add more information.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
69639-0101-01	Akynzeo	Helsinn Therapeutics (U.S.), Inc.	1	300 MG

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

AKYNZEO Pricing & Reimbursement

J8655 Private Payer Reimbursement

$404.22 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q3 2026

AKYNZEO CPT Administration Codes

CPT Code	Description
96367	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)

Not on the CMS JW / JZ list

CMS does not include Akynzeo (J8655) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing J8655. Wastage billing guide →

AKYNZEO Medically Unlikely Edits (MUE)

The most billing units of J8655 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 300 mg/0.5 mg.

Practitioner Office & Hospital Outpatient

1 unit / day

= 300 mg/0.5 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

AKYNZEO Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Chemotherapy-induced nausea and vomiting

Drug Class

Breast Cancer Resistance Protein Inhibitors [MoA]Cytochrome P450 3A4 Inhibitors [MoA]Neurokinin 1 Antagonists [MoA]P-Glycoprotein Inhibitors [MoA]Serotonin 3 Receptor Antagonists [MoA]Serotonin-3 Receptor Antagonist [EPC]Substance P/Neurokinin-1 Receptor Antagonist [EPC]

Frequently Asked Questions

Is there an available Akynzeo billing and coding guide?

Billing and coding information for AKYNZEO can be found through Helsinn Therapeutics. Visit Here →

Are there any available Akynzeo patient assistance programs?

AKYNZEO patient assistance information can be found through Helsinn Therapeutics. Visit Here →

Where can I find Akynzeo prescribing information?

AKYNZEO prescribing information can be found at the link below: Visit Here →

Where can I find Akynzeo side effect information?

Information regarding AKYNZEO's side effects can be found at MedlinePlus Visit Here →

Does billing AKYNZEO require JZ/JW wastage modifiers?

CMS does not include AKYNZEO (J8655) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing J8655. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.